DS-8201a + Ritonavir + Itraconazole
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasm Metastasis
Conditions
Neoplasm Metastasis
Trial Timeline
Jan 12, 2018 โ Sep 11, 2023
NCT ID
NCT03383692About DS-8201a + Ritonavir + Itraconazole
DS-8201a + Ritonavir + Itraconazole is a phase 1 stage product being developed by Daiichi Sankyo for Neoplasm Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03383692. Target conditions include Neoplasm Metastasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03383692 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasm Metastasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| EO-3021 + Ramucirumab (CYRAMZAยฎ) + Dostarlimab | CSPC Pharmaceutical Group Limited | Phase 1 | 32 |
| LY2780301 | Eli Lilly | Phase 1 | 33 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Abemaciclib + Clarithromycin | Eli Lilly | Phase 1 | 33 |
| Abemaciclib + Fulvestrant | Eli Lilly | Phase 2 | 52 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| enzastaurin + gemcitabine | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |